{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:30:38Z","timestamp":1793194238026,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA235375"],"award-info":[{"award-number":["R01CA235375"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["F99CA274651"],"award-info":[{"award-number":["F99CA274651"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA235375"],"award-info":[{"award-number":["R01CA235375"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006507","name":"MIT | Deshpande Center for Technological Innovation, Massachusetts Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012802","name":"Ragon Institute of MGH, MIT and Harvard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012802","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Mater."],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunotherapies such as immune checkpoint inhibitors are effective in treating several advanced cancers, but these treatments have had limited success in metastatic ovarian cancer. Here we engineered liposomal nanoparticles carrying a poly-\n                    <jats:sc>\u029f<\/jats:sc>\n                    -arginine\/poly-\n                    <jats:sc>\u029f<\/jats:sc>\n                    -glutamate coating that promotes their binding and retention on the surface of ovarian cancer cells. Covalent anchoring of the potent immunostimulatory cytokine interleukin-12 (IL-12) to phospholipid headgroups of the liposome core enabled the polymer-coated particles to concentrate IL-12 in disseminated ovarian cancer tumours following intraperitoneal administration. Shedding of the layer-by-layer coating and serum-protein-mediated extraction of IL-12-conjugated lipids from the liposomal core over time enabled IL-12 to disseminate in the tumour bed following rapid nanoparticle localization in tumour nodules. Optimized IL-12-polymer-coated nanoparticles promoted robust T cell accumulation in ascites and tumours in mouse models, extending survival compared with free IL-12 and sensitizing tumours to immune checkpoint inhibitors, eliciting strong immune responses and immune memory. Overall, these findings support the potential of these polymer-coated nanoparticles for the sustained delivery of IL-12 to disseminated metastatic ovarian cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41563-025-02390-9","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:04:55Z","timestamp":1761905095000},"page":"322-334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4035-0027","authenticated-orcid":false,"given":"Ivan S.","family":"Pires","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Covarrubias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-0482","authenticated-orcid":false,"given":"Victoria F.","family":"Gomerdinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8012-8340","authenticated-orcid":false,"given":"Coralie","family":"Backlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1247-7708","authenticated-orcid":false,"given":"Eduardo","family":"Nombera Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7211-8150","authenticated-orcid":false,"given":"Mae","family":"Pryor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorv","family":"Shanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6023-2789","authenticated-orcid":false,"given":"Ezra","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8175-3490","authenticated-orcid":false,"given":"Shengwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-7752","authenticated-orcid":false,"given":"Andrew J.","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0409-2454","authenticated-orcid":false,"given":"Mariane B.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikyung","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-1405","authenticated-orcid":false,"given":"Darrell J.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9835-192X","authenticated-orcid":false,"given":"Paula T.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2390_CR1","unstructured":"Arora, T., Mullangi, S. & Lekkala, M. R. Ovarian Cancer (StatPearls Publishing, 2023)."},{"key":"2390_CR2","doi-asserted-by":"crossref","unstructured":"Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J. Clin. 69, 280\u2013304 (2019).","DOI":"10.3322\/caac.21559"},{"key":"2390_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani, K. et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr. Oncol. 27, 87\u201397 (2020).","journal-title":"Curr. Oncol."},{"key":"2390_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman, A. J., Garrett-Thomson, S. C. & Lonberg, N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat. Rev. Drug Discov. 21, 509\u2013528 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2390_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","volume":"21","author":"S Upadhaya","year":"2022","unstructured":"Upadhaya, S., Neftelinov, S. T., Hodge, J. & Campbell, J. Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape. Nat. Rev. Drug Discov. 21, 482\u2013483 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2390_CR6","doi-asserted-by":"crossref","unstructured":"Chardin, L. & Leary, A. Immunotherapy in ovarian cancer: thinking beyond PD-1\/PD-L1. Front. Oncol. 11, 795547 (2021).","DOI":"10.3389\/fonc.2021.795547"},{"key":"2390_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311\u2013325 (2017).","journal-title":"Cancer Cell"},{"key":"2390_CR8","doi-asserted-by":"publisher","first-page":"2100035","DOI":"10.1002\/adtp.202100035","volume":"4","author":"IS Pires","year":"2021","unstructured":"Pires, I. S., Hammond, P. T. & Irvine, D. J. Engineering strategies for immunomodulatory cytokine therapies: challenges and clinical progress. Adv. Ther. 4, 2100035 (2021).","journal-title":"Adv. Ther."},{"key":"2390_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41551-021-00831-9","volume":"6","author":"Y Agarwal","year":"2022","unstructured":"Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129\u2013143 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"2390_CR10","doi-asserted-by":"crossref","unstructured":"Irvine, D. J. & Dane, E. L. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 20, 321\u2013334 (2020).","DOI":"10.1038\/s41577-019-0269-6"},{"key":"2390_CR11","doi-asserted-by":"crossref","unstructured":"Yang, Y. et al. Nanomedicine strategies for heating \u2018cold\u2019 ovarian cancer (OC): next evolution in immunotherapy of OC. Adv. Sci. 9, 2105523 (2022).","DOI":"10.1002\/advs.202202797"},{"key":"2390_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2217\/fon-2018-0423","volume":"15","author":"PH Thaker","year":"2019","unstructured":"Thaker, P. H., Borys, N., Fewell, J. & Anwer, K. GEN-1 immunotherapy for the treatment of ovarian cancer. Future Oncol. 15, 421\u2013438 (2019).","journal-title":"Future Oncol."},{"key":"2390_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.apsb.2023.08.014","volume":"14","author":"Y Lin","year":"2024","unstructured":"Lin, Y. et al. Immunostimulatory gene therapy combined with checkpoint blockade reshapes tumor microenvironment and enhances ovarian cancer immunotherapy. Acta Pharm. Sin. B 14, 854\u2013868 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"2390_CR14","doi-asserted-by":"publisher","first-page":"37513","DOI":"10.1021\/acsami.9b15178","volume":"11","author":"DC Wimalachandra","year":"2019","unstructured":"Wimalachandra, D. C. et al. Microfluidic-based immunomodulation of immune cells using upconversion nanoparticles in simulated blood vessel\u2013tumor system. ACS Appl. Mater. Interfaces 11, 37513\u201337523 (2019).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2390_CR15","doi-asserted-by":"publisher","first-page":"13343","DOI":"10.1021\/acsnano.0c05194","volume":"14","author":"K-C Mei","year":"2020","unstructured":"Mei, K.-C. et al. Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors. ACS Nano 14, 13343\u201313366 (2020).","journal-title":"ACS Nano"},{"key":"2390_CR16","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1021\/acs.bioconjchem.1c00139","volume":"32","author":"Y Kang","year":"2021","unstructured":"Kang, Y. et al. Large, anionic liposomes enable targeted intraperitoneal delivery of a TLR 7\/8 agonist to repolarize ovarian tumors\u2019 microenvironment. Bioconjug. Chem. 32, 1581\u20131592 (2021).","journal-title":"Bioconjug. Chem."},{"key":"2390_CR17","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1021\/acsnano.9b09213","volume":"14","author":"S Correa","year":"2020","unstructured":"Correa, S. et al. Tuning nanoparticle interactions with ovarian cancer through layer-by-layer modification of surface chemistry. ACS Nano 14, 2224\u20132237 (2020).","journal-title":"ACS Nano"},{"key":"2390_CR18","first-page":"e10453","volume":"7","author":"AE Barberio","year":"2022","unstructured":"Barberio, A. E. et al. Layer-by-layer interleukin-12 nanoparticles drive a safe and effective response in ovarian tumors. Bioeng Transl. Med. 7, e10453 (2022).","journal-title":"Bioeng Transl. Med."},{"key":"2390_CR19","doi-asserted-by":"publisher","first-page":"11238","DOI":"10.1021\/acsnano.0c03109","volume":"14","author":"AE Barberio","year":"2020","unstructured":"Barberio, A. E. et al. Cancer cell coating nanoparticles for optimal tumor-specific cytokine delivery. ACS Nano 14, 11238\u201311253 (2020).","journal-title":"ACS Nano"},{"key":"2390_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/10611860600864018","volume":"14","author":"R R\u00fcger","year":"2006","unstructured":"R\u00fcger, R., M\u00fcller, D., Fahr, A. & Kontermann, R. E. In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes. J. Drug Target 14, 576\u2013582 (2006).","journal-title":"J. Drug Target"},{"key":"2390_CR21","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1021\/bc900448f","volume":"21","author":"V Platt","year":"2010","unstructured":"Platt, V. et al. Influence of multivalent nitrilotriacetic acid lipid\u2212ligand affinity on the circulation half-life in mice of a liposome-attached His6 -protein. Bioconjug. Chem. 21, 892\u2013902 (2010).","journal-title":"Bioconjug. Chem."},{"key":"2390_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/chem.201803174","volume":"25","author":"JMJM Ravasco","year":"2019","unstructured":"Ravasco, J. M. J. M., Faustino, H., Trindade, A. & Gois, P. M. P. Bioconjugation with maleimides: a useful tool for chemical biology. Chem. Eur. 25, 43\u201359 (2019).","journal-title":"Chem. Eur."},{"key":"2390_CR23","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.1021\/acsnano.9b00792","volume":"13","author":"S Correa","year":"2019","unstructured":"Correa, S., Boehnke, N., Deiss-Yehiely, E. & Hammond, P. T. Solution conditions tune and optimize loading of therapeutic polyelectrolytes into layer-by-layer functionalized liposomes. ACS Nano 13, 5623\u20135634 (2019).","journal-title":"ACS Nano"},{"key":"2390_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1349-7006.1989.tb02336.x","volume":"80","author":"M Hashimoto","year":"1989","unstructured":"Hashimoto, M., Niwa, O., Nitta, Y., Takeichi, M. & Yokoro, K. Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J. Cancer Res. 80, 459\u2013463 (1989).","journal-title":"Jpn J. Cancer Res."},{"key":"2390_CR25","doi-asserted-by":"crossref","unstructured":"Pickering, A. J. et al. Layer-by-layer polymer functionalization improves nanoparticle penetration and glioblastoma targeting in the brain. ACS Nano 18, 4200\u20134216 (2024).","DOI":"10.1021\/acsnano.4c02084"},{"key":"2390_CR26","doi-asserted-by":"crossref","unstructured":"To\u0161i\u0107, I. et al. Lipidome-based targeting of STAT3-driven breast cancer cells using poly-\u029f-glutamic acid\u2013coated layer-by-layer nanoparticles. Mol. Cancer Ther. 20, 726\u2013738 (2021).","DOI":"10.1158\/1535-7163.MCT-20-0505"},{"key":"2390_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10147-021-01866-3","volume":"26","author":"Y Iwagoi","year":"2021","unstructured":"Iwagoi, Y. et al. Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III\u2013IV epithelial ovarian cancer. Int. J. Clin. Oncol. 26, 995\u20131004 (2021).","journal-title":"Int. J. Clin. Oncol."},{"key":"2390_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/bio.1112","volume":"24","author":"M Toyoshima","year":"2009","unstructured":"Toyoshima, M. et al. Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging. Luminescence 24, 324\u2013331 (2009).","journal-title":"Luminescence"},{"key":"2390_CR29","unstructured":"Nagao, S. et al. Intraperitoneal carboplatin for ovarian cancer\u2014a phase 2\/3 trial. N. Engl. J. Med. Evid. 2, EVIDoa2200225 (2023)."},{"key":"2390_CR30","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541\u20132548 (1997).","journal-title":"Blood"},{"key":"2390_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2162-3619-3-11","volume":"3","author":"MS Gokhale","year":"2014","unstructured":"Gokhale, M. S. et al. Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects. Exp. Hematol. Oncol. 3, 11 (2014).","journal-title":"Exp. Hematol. Oncol."},{"key":"2390_CR32","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1084\/jem.181.5.1893","volume":"181","author":"VM Eng","year":"1995","unstructured":"Eng, V. M. et al. The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon gamma in vivo. J. Exp. Med. 181, 1893\u20131898 (1995).","journal-title":"J. Exp. Med."},{"key":"2390_CR33","first-page":"1693","volume":"147","author":"BD Car","year":"1995","unstructured":"Car, B. D. et al. Role of interferon-gamma in interleukin 12-induced pathology in mice. Am. J. Pathol. 147, 1693\u20131707 (1995).","journal-title":"Am. J. Pathol."},{"key":"2390_CR34","doi-asserted-by":"crossref","unstructured":"Grigorian, A. & O\u2019Brien, C. B. Hepatotoxicity secondary to chemotherapy. J. Clin. Transl. Hepatol. 2, 95\u2013102 (2014).","DOI":"10.14218\/JCTH.2014.00011"},{"key":"2390_CR35","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1200\/JCO.2003.12.119","volume":"21","author":"JA Gollob","year":"2003","unstructured":"Gollob, J. A. et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol. 21, 2564\u20132573 (2003).","journal-title":"J. Clin. Oncol."},{"key":"2390_CR36","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.4049\/jimmunol.152.3.1253","volume":"152","author":"JS Orange","year":"1994","unstructured":"Orange, J. S., Wolf, S. F. & Biron, C. A. Effects of IL-12 on the response and susceptibility to experimental viral infections. J. Immunol. 152, 1253\u20131264 (1994).","journal-title":"J. Immunol."},{"key":"2390_CR37","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41551-022-00888-0","volume":"6","author":"A Mansurov","year":"2022","unstructured":"Mansurov, A. et al. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat. Biomed. Eng. 6, 819\u2013829 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"2390_CR38","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/cells12141912","volume":"12","author":"K Ok\u0142a","year":"2023","unstructured":"Ok\u0142a, K. Myeloid-derived suppressor cells (MDSCs) in ovarian cancer\u2014looking back and forward. Cells 12, 1912 (2023).","journal-title":"Cells"},{"key":"2390_CR39","first-page":"2875","volume":"29","author":"RL Giuntoli","year":"2009","unstructured":"Giuntoli, R. L. et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 29, 2875\u20132884 (2009).","journal-title":"Anticancer Res."},{"key":"2390_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0304-4157(74)90001-X","volume":"344","author":"KWA Wirtz","year":"1974","unstructured":"Wirtz, K. W. A. Transfer of phospholipids between membrane. Biochim. Biophys. Acta Rev. Biomembr. 344, 95\u2013117 (1974).","journal-title":"Biochim. Biophys. Acta Rev. Biomembr."},{"key":"2390_CR41","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0006-3495(03)74859-0","volume":"84","author":"MSC Abreu","year":"2003","unstructured":"Abreu, M. S. C., Estronca, L. M. B. B., Moreno, M. J. & Vaz, W. L. C. Binding of a fluorescent lipid amphiphile to albumin and its transfer to lipid bilayer membranes. Biophys. J. 84, 386\u2013399 (2003).","journal-title":"Biophys. J."},{"key":"2390_CR42","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/s41596-018-0033-6","volume":"13","author":"M Doktorova","year":"2018","unstructured":"Doktorova, M. et al. Preparation of asymmetric phospholipid vesicles for use as cell membrane models. Nat. Protoc. 13, 2086\u20132101 (2018).","journal-title":"Nat. Protoc."},{"key":"2390_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1388-1981(99)00077-3","volume":"1439","author":"G Wolfbauer","year":"1999","unstructured":"Wolfbauer, G., Albers, J. J. & Oram, J. F. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1439, 65\u201376 (1999).","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"2390_CR44","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1021\/bi00065a025","volume":"32","author":"SJ Slater","year":"1993","unstructured":"Slater, S. J., Ho, C., Taddeo, F. J., Kelly, M. B. & Stubbs, C. D. Contribution of hydrogen bonding to lipid-lipid interactions in membranes and the role of lipid order: effects of cholesterol, increased phospholipid unsaturation, and ethanol. Biochemistry 32, 3714\u20133721 (1993).","journal-title":"Biochemistry"},{"key":"2390_CR45","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.7150\/thno.18136","volume":"7","author":"X Zhu","year":"2017","unstructured":"Zhu, X. et al. Surface de-PEGylation controls nanoparticle-mediated siRNA delivery in vitro and in vivo. Theranostics 7, 1990\u20132002 (2017).","journal-title":"Theranostics"},{"key":"2390_CR46","doi-asserted-by":"publisher","first-page":"22720","DOI":"10.1039\/C8NR07755J","volume":"10","author":"R M\u00fcnter","year":"2018","unstructured":"M\u00fcnter, R. et al. Dissociation of fluorescently labeled lipids from liposomes in biological environments challenges the interpretation of uptake studies. Nanoscale 10, 22720\u201322724 (2018).","journal-title":"Nanoscale"},{"key":"2390_CR47","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1200\/JCO.2022.40.16_suppl.4508","volume":"40","author":"K Chamie","year":"2022","unstructured":"Chamie, K. et al. Final clinical results of pivotal trial of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). J. Clin. Oncol. 40, 4508 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2390_CR48","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1038\/s41590-024-01925-7","volume":"25","author":"L Santollani","year":"2024","unstructured":"Santollani, L. et al. Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity. Nat. Immunol. 25, 1820\u20131829 (2024).","journal-title":"Nat. Immunol."},{"key":"2390_CR49","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/14712598.2020.1738379","volume":"20","author":"KM Knudson","year":"2020","unstructured":"Knudson, K. M., Hodge, J. W., Schlom, J. & Gameiro, S. R. Rationale for IL-15 superagonists in cancer immunotherapy. Expert Opin. Biol. Ther. 20, 705\u2013709 (2020).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2390_CR50","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi, J. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol. 39, 3671\u20133681 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2390_CR51","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1200\/JCO.19.02059","volume":"38","author":"D Zamarin","year":"2020","unstructured":"Zamarin, D. et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG Oncology study. J. Clin. Oncol. 38, 1814\u20131823 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2390_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101134","volume":"41","author":"F Li","year":"2021","unstructured":"Li, F. et al. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. EClinicalMedicine 41, 101134 (2021).","journal-title":"EClinicalMedicine"},{"key":"2390_CR53","doi-asserted-by":"crossref","unstructured":"Spranger, S. et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).","DOI":"10.1126\/scitranslmed.3006504"},{"key":"2390_CR54","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko, K. et al. IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112, 1501\u20131509 (2015).","journal-title":"Br. J. Cancer"},{"key":"2390_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173\u2013185 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2390_CR56","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187\u20132194 (2010).","journal-title":"J. Exp. Med."},{"key":"2390_CR57","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2018","unstructured":"Simon, S. & Labarriere, N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology 7, e1364828 (2018).","journal-title":"Oncoimmunology"},{"key":"2390_CR58","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI59806","volume":"122","author":"Z-Z Yang","year":"2012","unstructured":"Yang, Z.-Z. et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J. Clin. Invest. 122, 1271\u20131282 (2012).","journal-title":"J. Clin. Invest."},{"key":"2390_CR59","doi-asserted-by":"crossref","unstructured":"Lasek, W., Zago\u017cd\u017con, R. & Jakobisiak, M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol. Immunother. 63, 419\u2013435 (2014).","DOI":"10.1007\/s00262-014-1523-1"},{"key":"2390_CR60","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","volume":"21","author":"KF Roby","year":"2000","unstructured":"Roby, K. F. et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21, 585\u2013591 (2000).","journal-title":"Carcinogenesis"},{"key":"2390_CR61","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","volume":"76","author":"J Walton","year":"2016","unstructured":"Walton, J. et al. CRISPR\/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Res. 76, 6118\u20136129 (2016).","journal-title":"Cancer Res."},{"key":"2390_CR62","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1158\/2159-8290.CD-20-0818","volume":"11","author":"S Iyer","year":"2021","unstructured":"Iyer, S. et al. Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy. Cancer Discov. 11, 384\u2013407 (2021).","journal-title":"Cancer Discov."},{"key":"2390_CR63","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13048-023-01313-z","volume":"16","author":"S Farokhi Boroujeni","year":"2023","unstructured":"Farokhi Boroujeni, S. et al. BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy. J. Ovarian Res. 16, 231 (2023).","journal-title":"J. Ovarian Res."},{"key":"2390_CR64","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/s41416-022-01763-0","volume":"126","author":"S Seitz","year":"2022","unstructured":"Seitz, S. et al. CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. Br. J. Cancer 126, 1470\u20131480 (2022).","journal-title":"Br. J. Cancer"},{"key":"2390_CR65","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2767-9764.CRC-22-0017","volume":"2","author":"GM Rodriguez","year":"2022","unstructured":"Rodriguez, G. M. et al. The tumor immune profile of murine ovarian cancer models: an essential tool for ovarian cancer immunotherapy research. Cancer Res. Commun. 2, 417\u2013433 (2022).","journal-title":"Cancer Res. Commun."},{"key":"2390_CR66","doi-asserted-by":"publisher","first-page":"e0155189","DOI":"10.1371\/journal.pone.0155189","volume":"11","author":"SD Martin","year":"2016","unstructured":"Martin, S. D. et al. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS ONE 11, e0155189 (2016).","journal-title":"PLoS ONE"},{"key":"2390_CR67","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175\u2013196 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2390_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01385-8","volume":"8","author":"P Wang","year":"2017","unstructured":"Wang, P. et al. Re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat. Commun. 8, 1395 (2017).","journal-title":"Nat. Commun."},{"key":"2390_CR69","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/nm.4200","volume":"22","author":"KD Moynihan","year":"2016","unstructured":"Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402\u20131410 (2016).","journal-title":"Nat. Med."},{"key":"2390_CR70","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature12978","volume":"507","author":"H Liu","year":"2014","unstructured":"Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519\u2013522 (2014).","journal-title":"Nature"},{"key":"2390_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nbt0197-35","volume":"15","author":"GJ Lieschke","year":"1997","unstructured":"Lieschke, G. J., Rao, P. K., Gately, M. K. & Mulligan, R. C. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat. Biotechnol. 15, 35\u201340 (1997).","journal-title":"Nat. Biotechnol."},{"key":"2390_CR72","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","volume":"56","author":"K Han","year":"2011","unstructured":"Han, K. et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56, 804\u2013810 (2011).","journal-title":"Cytokine"},{"key":"2390_CR73","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0003-2697(80)90269-9","volume":"104","author":"JCM Stewart","year":"1980","unstructured":"Stewart, J. C. M. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104, 10\u201314 (1980).","journal-title":"Anal. Biochem."},{"key":"2390_CR74","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"}],"container-title":["Nature Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41563-025-02390-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41563-025-02390-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41563-025-02390-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:02:22Z","timestamp":1770130942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41563-025-02390-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2390"],"URL":"https:\/\/doi.org\/10.1038\/s41563-025-02390-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.05.602135","asserted-by":"object"}]},"ISSN":["1476-1122","1476-4660"],"issn-type":[{"value":"1476-1122","type":"print"},{"value":"1476-4660","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.S.P., P.T.H. and D.J.I. are inventors on a patent filed by the Massachusetts Institute of Technology relating to these LbL NP therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}